FDA Law Blog

MARCH 12, 2024

As Abbvie wrote: “While your letter refers to ‘sham’ patents and concerns about ‘abusing the patent system,’ the FTC’s letter makes no assertions that these patents were ill-gotten or are otherwise illegitimate. Rather, the FTC questioned whether these patents meet the statutory and regulatory criteria for listing in the Orange Book.

Provider 45

Provider Manufacturing IT Illness 45

GeriPal

MARCH 13, 2025

Eric 01:44 And we’re going to be talking about the roots of palliative care, and I think importantly, not just looking back, but what does that mean for our future as hospice and palliative care providers. If you read just one, read Palliative Medicine – Just Another Specialty ? by Kearney. I promise its short.

IT 104

IT Patient-Centered Families Family 104

GeriPal

MAY 12, 2022

Raj faced in pain management: access to opioids, corruption, a system that doesn’t see addressing suffering as a priority. Prognosis communication and the subtle ways we may communicate it without intention. Social pain and loneliness. Community-based palliative care networks . Raj’s reflections on the state of palliative care in the US. Transcript.

Community 115

Community IT Relationship Healthcare 115

FDA Law Blog

JANUARY 9, 2024

After its enactment in 2003, successive administrations thwarted its implementation by declining to certify to Congress that importation will pose no additional risk to public health and safety and will result in a significant reduction in cost to American consumers, as the statute requires. See 21 C.F.R. 251.5; § 251.6(c). See 21 C.F.R.

Supply Chain 59

Supply Chain Manufacturing Chronic Condition Government 59